Loading
companiesCompany
Erasca
Erasca develops pills that shut down the RAS signalling pathway, one of the most common drivers of cancer. Its two lead drugs aim to block all forms of RAS or KRAS rather than a single mutation.
Overview
Erasca is a San Diego clinical-stage company focused on RAS/MAPK pathway-driven cancers. Its lead candidates are ERAS-0015, a pan-RAS molecular glue in the phase 1 AURORAS-1 trial in RAS-mutant solid tumours, and ERAS-4001, a pan-KRAS inhibitor in the phase 1 BOREALIS-1 trial in KRAS-mutant solid tumours. Earlier programmes include ERAS-007 (an ERK inhibitor, phase 1b/2 HERKULES-3 in colorectal cancer combinations) and ERAS-801 (phase 1 THUNDERBOLT-1 in recurrent glioblastoma), while the company is exploring strategic alternatives for ERAS-12, an EGFR domain 2/3 bispecific antibody. Erasca completed its Nasdaq IPO in July 2021 with gross proceeds of 345 million US dollars and has since completed several follow-on offerings.
Headquarters
San Diego, CA, US
Scorecard
All companies#417of 1244 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 2 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| IPO · 21,562,500 shares at 16 US dollars including full exercise of the underwriters' option; closed 20 July 2021 | 2021 | $345M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Biotech · ERAS
Stage
Public
Website
Phase 3small molecule
Naporafenib is an experimental small-molecule drug from Erasca in phase 3 trials for melanoma, with its target not yet stated publicly.
Notes
top- Founding year and follow-on offering amounts not sourced. Naporafenib is not listed on the current pipeline page.
Similar pages
- CompanyKumquat Biosciences
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer.
- PersonKevan M. Shokat
Shares KRAS & RAS inhibitors, KRAS, Small-molecule kinase inhibitors, Colorectal cancer.
- CompanyQuanta Therapeutics
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer.
- TargetSHP2 (PTPN11)
Shares KRAS & RAS inhibitors, KRAS, Small-molecule kinase inhibitors, Colorectal cancer.
- TrialJAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
Shares KRAS & RAS inhibitors, Small-molecule kinase inhibitors, Colorectal cancer.
- TrialStudy of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer.
- CompanyBridgeBio Oncology Therapeutics
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer.
- Key paperKRAS G12C metastatic colorectal cancer: specific features of a new emerging target population
Shares KRAS & RAS inhibitors, KRAS, Colorectal cancer.
cancers
fronts
technologies
targets
drugs
Phase 3small molecule